Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04

    • br The last century has witnessed incredible progresses in

    2018-10-23


    The last century has witnessed incredible progresses in the control of infectious diseases. However, respiratory pathogens continue to threaten humans and cause serious public health and economic problems. Not only emerging pathogens but also viruses that have been known for a while continue to cause widespread issues (). Despite the relative efficacy of the inactivated vaccine against influenza A viruses (IAV) has been shown for many years, this virus is still responsible for seasonal widespread morbidity and mortality. These outbreaks are usually associated with mild symptoms but can also result in 3 to 5 million cases of severe illnesses, especially amongst elderly and young children. Influenza virus still accounts for 250,000 to 500,000 deaths each year during epidemic episodes (). This is due to the continuous antigenic drift that leads to vaccine mismatch and therefore negatively impacts on its effectiveness (). Moreover, more sporadically, pandemics due to highly virulent strains or transversal infections of animal strains to humans represent another important threat (). In this context, it is of the utmost importance to urgently develop universal influenza vaccines. Current vaccines are yearly updated on the basis of the circulating strains but unfortunately mainly generate neutralizing Ketorolac tromethamine salt (Abs) directed against epitopes contained in highly variable regions (). Nevertheless pre-clinical studies have demonstrated promising data through the generation of neutralizing Abs against conserved regions such as the helix-A of the surface glycoprotein hemagglutinin (HA) () but these observations have not yet been translated into humans. Amongst additional functions triggered by Abs, Ab-dependent cellular cytotoxicity (ADCC) mediates antiviral activities through the binding of cell surface Ags by IgG subtypes on target cells. This ultimately leads to the lysis of the target cells by secreted lytic enzymes from effector cells. This secretion follows the recognition of Fc region of surface bound Abs by FcγRIIIα (CD16)-expressing cytotoxic effector cells from both innate and adaptive immunity such as Natural Killer (NK) cells or CD8 T cells. ADCC directed against IAV has been recognized for a long time(). Since this class of Abs can target much more conserved proteins, understanding ADCC mechanisms during IAV infection might help in the development of universal influenza vaccines. For instance, a vaccine trial in HIV patients has been demonstrated protective in part through ADCC-mediating Abs(). In this issue, Vanderven and colleagues evidence in human samples from healthy influenza-exposed adults or symptomatic donors the existence of IAV-specific Abs capable of ADCC activity through NK cells (). Interestingly these opsonizing Abs are directed against the highly conserved internal viral proteins nucleoprotein (NP) and matrix 1(M1) (~90% of identity in amino acid sequences between strains) from two different strains of IAV (H1N1/2009pdm and H3N2/2005). An increase for such cross-protective Abs was found in sera of naturally IAV-exposed humans suggesting that this class of Abs can potentially mediate heterologous response to various IAV strains during active infection. However, authors failed to detect rise in NK cell-mediated ADCC activity in volunteers experimentally exposed to IAV (H3N2/2005). The reasons for such a discrepancy are currently unknown. It is possible that the route/dose of infection as well as the strain used matters in the development of NK cell activating Abs. Other clinical studies investigating the contribution of these parameters will be informative to answer this question. The presence and functionality of NP- and M1-specific NK cell-mediated ADCC in animal models including non-human primates has already been demonstrated (). From a mechanistic point of view, the relevance of ADCC mediated against internal proteins remains puzzling. Given that NP and M1 are only minimally exposed at the cell surface during IAV life cycle, it will be important to determine the precise molecular/cellular mechanisms underlying NK cell-mediated ADCC. Although these Abs could mediate direct protection through opsonization of infected/dying cells, another explanation might involve indirect mechanisms (e.g. cytokine production or immune complex formation) that could lead to enhanced immune responses.